Harmony Biosciences Holdings, Inc. filed a Current Report on Form 8-K on August 4, 2026, announcing the availability of its financial results for the quarter ended June 30, 2026, along with an investor presentation posted to its website on the same date.

Key Highlights

  • Quarterly results announced: The company issued a press release on August 4, 2026, reporting financial results for the quarter ended June 30, 2026.
  • Investor presentation posted: An investor presentation was posted to the company's investor relations website at ttps://ir.harmonybiosciences.com on August 4, 2026.
  • Exhibits furnished: Exhibit 99.1 is the press release and Exhibit 99.2 is the investor presentation, both dated August 4, 2026.
  • Signing officer: The report was signed by Stephen Mollichella, Senior Vice President, Controller and Interim Principal Financial Officer.
  • Furnished, not filed: The filing and its exhibits "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," according to the filing.

Harmony Biosciences Reports Q2 2026 Results and Posts Investor Presentation

According to the filing, Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) submitted a Current Report on Form 8-K to the U.S. Securities and Exchange Commission on August 4, 2026. The report covers two disclosure items: Item 2.02, relating to results of operations and financial condition, and Item 7.01, relating to Regulation FD disclosure. The actual financial figures for the quarter ended June 30, 2026, are contained in the attached press release (Exhibit 99.1) and are not detailed within the body of the 8-K itself.

Under Item 7.01, the company disclosed that it posted an investor presentation to its website on August 4, 2026. The filing notes that "the Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others." The filing further states that the investor presentation "speaks only as of the date of this Current Report" and that the company undertakes no obligation to publicly update or revise the information contained in it, except as may be required by law.

The filing notes that the investor presentation contains statements intended as "forward-looking statements" that are subject to cautionary language set forth in the exhibit. The company references risks discussed in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as factors that could cause actual results to differ materially from any forward-looking statements.

What Was Disclosed

Harmony Biosciences filed an 8-K on August 4, 2026, to announce second-quarter 2026 financial results via an attached press release and to disclose an investor presentation posted to its website, both furnished but not deemed filed under the Exchange Act.